Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 17 clinical trials
Study to Assess Safety Tolerability Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.

progressive disease
chronic myelomonocytic leukemia
secondary aml
multiple myeloma
  • 05 Jun, 2021
  • 22 locations
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

This phase I trial studies the side effects and best dose of duvelisib when given together with nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Duvelisib

platelet count
beta human chorionic gonadotrophin
chronic lymphocytic leukemia
b-cell lymphoma
lymphoid leukemia
  • 05 Feb, 2021
  • 1 location
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome. The drugs involved in this study are: Venetoclax R-EPOCH: Rituximab Etoposide Prednisone Vincristine Sulfate (Oncovin) Cyclophosphamide Doxorubicin Hydrochloride (Hydroxydaunomycin) R-CHOP: Rituximab Cyclophosphamide Vincristine …

  • 29 Jan, 2021
  • 4 locations
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

lysis of tumor cells. The investigators propose to evaluate the efficacy, safety and tolerability of blinatumomab administered after R-CHOP debulking therapy in patients with Richter Syndrome (RS

  • 22 Jan, 2021
  • 42 locations
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

  • 15 Feb, 2021
  • 12 locations
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

refractory classical hodgkin lymphoma
b-cell lymphoma
  • 17 Jun, 2021
  • 9 locations
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

platelet count
diffuse large b-cell lymphoma
b-cell lymphoma
neutrophil count
gilbert's syndrome
  • 22 May, 2021
  • 8 locations
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

monoclonal protein
lymphocytic leukemia
mantle cell lymphoma
richter syndrome
  • 16 Jun, 2021
  • 3 locations
Atezolizumab Gemcitabine Oxaliplatin and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma

This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help …

gilbert's syndrome
marginal zone lymphoma
HIV Infection
ct scan
  • 26 Feb, 2021
  • 2 locations
Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma

This phase I trial studies best dose and how well copanlisib when given together with nivolumab works in treating participants with Richter's transformation or transformed indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as …

beta human chorionic gonadotrophin
b-cell lymphoma
conjugated bilirubin
stem cell transplantation
  • 19 Feb, 2021
  • 4 locations